Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection

Guoxiang Xie; Xiaoning Wang; Runmin Wei; Jingye Wang; Aihua Zhao; Tianlu Chen; Yixing Wang; Hua Zhang; Zhun Xiao; Xinzhu Liu; Youping Deng; Linda Wong; Jun Panee; Cynthia Rajani; Yan Ni; Sandi Kwee; Hua Bian; Xin Gao; Ping Liu; Wei Jia

doi:10.1101/2020.01.02.20016352

ABSTRACT

Background & Aims Accurate and noninvasive diagnosis and staging of liver fibrosis is essential for effective clinical management of chronic liver disease (CLD). We aimed to identify serum metabolite markers that reliably predict the stage of fibrosis in CLD patients.

Methods We quantitatively profiled serum metabolites of participants in 2 independent cohorts. Based on the metabolomics data from Cohort 1 (504 HBV associated liver fibrosis patients and 502 normal controls, NC), we selected a panel of 4 predictive metabolite markers. Consequently, we constructed 3 machine learning models with the 4 metabolite markers using random forest (RF), to differentiate CLD patients from normal controls (NC), to differentiate cirrhosis patients from fibrosis patients, and to differentiate advanced fibrosis from early fibrosis, respectively.

Results The panel of 4 metabolite markers consisted of taurocholate, tyrosine, valine, and linoelaidic acid. The RF models of the metabolite panel demonstrated the strongest stratification ability in Cohort 1 to diagnose CLD patients from NC (area under the receiver operating characteristic curve (AUROC) = 0.997 and the precision-recall curve (AUPR) = 0.994), to differentiate fibrosis from cirrhosis (0.941, 0.870), and to stage liver fibrosis (0.918, 0.892). The diagnostic accuracy of the models was further validated in an independent Cohort 2 consisting of 300 CLD patients with chronic HBV infection and 90 NC. The AUCs of the models were consistently higher than APRI, FIB-4 and AST/ALT ratio, with both greater sensitivity and specificity.

Conclusion Our study showed that this 4-metabolite panel has potential usefulness in clinical assessments of CLD progression.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was financially supported by the National Key R&D Program of China (2017YFC0906800), the National Institutes of Health/National Cancer Institute Grant 1U01CA188387-01A1, the National Natural Science Foundation of China (81160439, 81573873), the National Key R&D Program of China (2017YFC0906800), the Natural Science Foundation of Shanghai, China (14ZR1441400, 12ZR1432300), China Postdoctoral Science Foundation funded project, China (2016T90381, 2015M581652), and E-institutes of Shanghai Municipal Education Commission, China (E03008, 085ZY1205). The funding sources did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Financial support: This study was financially supported by the National Key R&D Program of China (2017YFC0906800), the National Institutes of Health/National Cancer Institute Grant 1U01CA188387-01A1, the National Natural Science Foundation of China (81160439, 81573873), the National Key R&D Program of China (2017YFC0906800), the Natural Science Foundation of Shanghai, China (14ZR1441400, 12ZR1432300), China Postdoctoral Science Foundation funded project, China (2016T90381, 2015M581652), and E-institutes of Shanghai Municipal Education Commission, China (E03008, 085ZY1205). The funding sources did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
DISCLOSURES: All authors read and approved the final manuscript and declared no conflicts of interest.

Data Availability

All the data supporting the findings of this study are available within the article and its Supplementary Information files or from the corresponding author upon reasonable request.